依洛尤单抗对心肌梗死后他汀治疗患者冠状动脉斑块表型与负荷的影响
本研究纳入非ST段抬高型心肌梗死患者,随机接受每月依洛尤单抗420 mg(n=80)或安慰剂(n=81)治疗52周,采用系列OCT和IVUS评估非罪犯血管匹配节段的斑块变化。依洛尤单抗组最小纤维帽厚度增加更明显(+42.7 vs +21.5 μm,P=0.015),最大脂质弧减小更多(-57.5° vs -31.4°,P=0.04),斑块体积百分比回退更显著(-2.29% vs -0.61%,P=0.009)。
要点
- 依洛尤单抗组最小纤维帽厚度增加42.7 μm,安慰剂组增加21.5 μm(P=0.015)。
- 依洛尤单抗组最大脂质弧减少57.5°,安慰剂组减少31.4°(P=0.04)。
- 依洛尤单抗组斑块体积百分比回退2.29%,安慰剂组回退0.61%(P=0.009)。
核心结论
- 非ST段抬高型心肌梗死后他汀联合依洛尤单抗治疗可使冠状动脉粥样硬化发生与稳定和回退一致的有利变化,这为急性冠脉综合征后达到极低LDL-C水平所观察到的临床结局改善提供了潜在机制。
研究设计与样本
- 随机、安慰剂对照研究,非ST段抬高型心肌梗死患者接受每月依洛尤单抗420 mg(n=80)或安慰剂(n=81)治疗52周,系列OCT和IVUS成像评估非罪犯血管匹配动脉节段,随访时135例有可评估影像。
关键影像表现/征象
- 依洛尤单抗组整个动脉节段最小纤维帽厚度增加+42.7 μm,安慰剂组增加+21.5 μm(P=0.015)。
- 依洛尤单抗组整个动脉节段最大脂质弧减少-57.5°,安慰剂组减少-31.4°(P=0.04)。
- 依洛尤单抗组巨噬细胞指数减少-3.17 mm,安慰剂组减少-1.45 mm(P=0.04)。
- 两组微通道和钙化变化无差异。
诊断标准与关键数值
- 主要分析指标为整个成像动脉节段最小纤维帽厚度和最大脂质弧的变化。
- 依洛尤单抗组LDL-C为28.1 mg/dL,安慰剂组为87.2 mg/dL(P<0.001)。
- 依洛尤单抗组斑块体积百分比变化为-2.29%±0.47%,安慰剂组为-0.61%±0.46%(P=0.009)。
临床应用与阅片要点
- 对于心肌梗死后他汀治疗患者,OCT可评估纤维帽厚度、脂质弧和巨噬细胞指数等斑块易损性特征。
- 依洛尤单抗联合他汀与斑块稳定和回退的影像学改变相关,但微通道和钙化未见组间差异。
局限性
- 随访时135例有可评估影像,原文未报告其余患者的影像不可评估原因。
- 原文未报告研究是否单中心、是否回顾性及样本量估算依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The proprotein convertase subtilisin kexin type-9 inhibitor evolocumab produced coronary atheroma regression in statin-treated patients.
OBJECTIVES: The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition.
METHODS: Patients with a non-ST-segment elevation myocardial infarction were treated with monthly evolocumab 420 mg (n = 80) or placebo (n = 81) for 52 weeks. Patients underwent serial OCT and intravascular ultrasound imaging within a matched arterial segment of a nonculprit vessel. The primary analysis determined the change in the minimum fibrous cap thickness and maximum lipid arc throughout the imaged arterial segment. Additional analyses determined changes in OCT features in lipid-rich plaque regions and plaque burden. Safety and tolerability were evaluated.
RESULTS: Among treated patients (age 60.5 ± 9.6 years; 28.6% women; low-density lipoprotein cholesterol [LDL-C], 141.3 ± 33.1 mg/dL), 135 had evaluable imaging at follow-up. The evolocumab group achieved lower LDL-C levels (28.1 vs 87.2 mg/dL; P < 0.001). The evolocumab group demonstrated a greater increase in minimum fibrous cap thickness (+42.7 vs +21.5 μm; P = 0.015) and decrease in maximum lipid arc (-57.5o vs. -31.4o; P = 0.04) and macrophage index (-3.17 vs -1.45 mm; P = 0.04) throughout the arterial segment. Similar benefits of evolocumab were observed in lipid-rich plaque regions. Greater regression of percent atheroma volume was observed with evolocumab compared with placebo (-2.29% ± 0.47% vs -0.61% ± 0.46%; P = 0.009). The groups did not differ regarding changes in microchannels or calcium.
CONCLUSIONS: The combination of statin and evolocumab after a non-ST-segment elevation myocardial infarction produces favorable changes in coronary atherosclerosis consistent with stabilization and regression. This demonstrates a potential mechanism for the improved clinical outcomes observed achieving very low LDL-C levels following an acute coronary syndrome. (Imaging of Coronary Plaques in Participants Treated With Evolocumab; NCT03570697).
引用
- Nicholls, Kataoka, Nissen, et al. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction. JACC Cardiovasc Imaging. 2022. PMID: 35431172. doi:10.1016/j.jcmg.2022.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。